Macsart Beta 25 Tablet ER is a combination antihypertensive medication containing Telmisartan 40 mg and Metoprolol Succinate 25 mg, formulated for extended release to provide sustained blood pressure control. Telmisartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor, thereby reducing vasoconstriction and aldosterone secretion, leading to decreased peripheral resistance and lowered blood pressure. Metoprolol Succinate is a cardioselective beta-1 adrenergic receptor blocker that reduces heart rate, myocardial contractility, and cardiac output, contributing to antihypertensive effects and improved cardiac function. The combination of these two agents offers complementary mechanisms to effectively manage hypertension, reduce the risk of cardiovascular events, and improve outcomes in patients with coexisting conditions such as ischemic heart disease or heart failure. Macsart Beta 25 Tablet ER is indicated for the treatment of essential hypertension and may be used in patients requiring multiple antihypertensive agents for optimal blood pressure control. The extended-release formulation ensures once-daily dosing, enhancing patient compliance. Caution is advised in patients with bradycardia, heart block, or severe hepatic impairment. Regular monitoring of blood pressure, renal function, and electrolytes is recommended during therapy.